Close Menu

Oxford Nanopore Technologies R10.3 Nanopore Chemistry

Jan 17, 2020

Oxford Nanopore Technologies has released flow cells using the R10.3 nanopore chemistry. It is currently available for MinIon and PromethIon sequencers and will be available for Flongle flow cells at a later time. The R10.3 chemistry, which is suitable for use with the LSK109 kit at launch, improves on the R10. Like the R10, it uses a pore with a longer barrel and a dual reader head, which improves resolution of homopolymers and consensus accuracy. Compared to the R10, it has increased throughput and capture, is compatible with PromethIon flow cells, has input amounts closer to the R9.4.1 chemistry, and has improved raw accuracy to match the R9.4.1 and to support enhanced variant calling.

More Like This

Jan 15, 2021

Twist Bioscience Synthetic RNA Controls for SARS-CoV-2 UK Variant

Twist Bioscience has begun shipping new synthetic RNA reference controls for SARS-CoV-2 that include the new variant strain of the virus (B1.1.7 lineage, variant under investigation VUI-202012/01) identified in the UK. As the new strain contains multiple mutations in the spike protein and other areas of the viral genome, some of the RT-PCR probes used widely in COVID-19 testing no longer detect the S gene that codes for the spike protein, which can lead to false negative test results. Synthetic controls for this specific mutation will enable test developers to update their testing protocols, Twist said.

Jan 14, 2021

Becton Dickinson AbSeq Immune Discovery Panel

Becton Dickinson has launched a single-tube antibody-oligo-based discovery tool called the BD AbSeq Immune Discovery Panel (IDP). The panel contains 30 different pre-titrated antibodies targeting most major immune markers, is supplied in a dried format, and allows researchers to include additional immune markers of interest. It is designed for the BD Rhapsody Single-Cell Analysis System, and intended to be used alongside protein, RNA, and multiplexing assays to enable sequencing-based immune cell phenotyping.

Jan 13, 2021

New England Biolabs Luna SARS-CoV-2 RT-qPCR Multiplex RUO Assay Kit

New England Biolabs has released the research-use-only Luna SARS-CoV-2 RT-qPCR Multiplex Assay Kit, which enables multiplex testing of up to 94 samples in a single 96-well plate with the additional capacity to support sample pooling and high-throughput applications using 384-well plates. The kit detects two separate regions of the SARS-CoV-2 N gene (N1 and N2) in addition to the human RNase P gene internal control, based on sequences provided by the US Centers for Disease Control and Prevention. The probes have been modified to detect N1 and N2 via two different fluorophores — HEX and FAM, respectively — for simultaneous fluorescence detection on two different channels of a real-time instrument. To reduce the risk of carryover contamination between reactions, the master mix includes dUTP and a unique, thermolabile UDG that offers significant benefits over the standard E. coli UDG, NEB said.

Jan 11, 2021

Seqster Platform Version 7.1 on Microsoft Azure

Seqster has released version 7.1 of its core technology platform on the Microsoft Azure cloud. Seqster is a comprehensive platform for accessing secure, longitudinal real-world data such as electronic health records, individual genomic profiles, and fitness wearables data in real time for healthcare enterprises. The health data management company is using Azure Key Vault, storage containers, and Azure Kubernetes Service "serverless" technology for security and scalability on the Microsoft cloud service. Features in this deployment include single-sign-on authentication, 21 CFR Part 11 compliance for clinical trial data management, and white-label branding, the company said. 

Jan 07, 2021

Diagenode D-Plex Small RNA DNBSEQ Kit

Diagenode has launched the D-Plex Small RNA DNBSEQ Kit, a small RNA sequencing product specifically formatted for MGI's DNBSEQ sequencers. The kit is based on a tailing and template switching technology that delivers a ligation-free method for RNA library preparation from small RNA input amounts as low as 10 picograms. The technology also enables detection of diverse and novel transcripts, ensuring realistic representation of the small non-coding RNA transcriptome and avoiding biased miRNA enrichment as with ligation methods, the company said. Furthermore, the kit has been validated for liquid biopsy applications, Diagenode said. The kit is available in a 24-reaction format with two sets of DNBSEQ barcodes available.

Jan 04, 2021

Analytical BioSciences OmniBrowser

Analytical BioSciences has launched OmniBrowser, a curated web portal for single-cell RNA-seq data visualization and analysis for drug discovery and development. OmniBrowser was designed specifically to support biologists with limited programming experience, and its underlying curated database features more than 1,490 datasets, 680 studies, 18,000 clusters, and 21 million cells, and is constantly updated, the company said. The platform provides web-based tools for dataset selection; dimensional reduction; differential gene expression; correlation analysis; marker gene information; Gene Ontology analysis; supervised annotation; and metadata analysis. OmniBrowser also provides multiple large-scale data-processing functions including gene search and cell ontology, the company said.

Dec 28, 2020

Eurofins Genomics SARS-CoV-2 NGS Service, ARTIC Oligo Mix

Eurofins Genomics has launched a SARS-CoV-2 next-generation sequencing service providing full-length viral genome sequences, and will shortly launch its ARTIC NGS oligo mix. The service and oligo mix are based on a protocol by the ARTIC consortium, which is used for SARS-CoV-2 sequencing worldwide. The ARTIC approach utilizes an oligo pool for multiplexed PCR amplification of the complete viral genome. Eurofins Genomics said that it optimized the formulation of the oligo pool for highest performance and uniformity of coverage for the full-length viral genome. Eurofins is offering part of its sequencing capacity for free to public healthcare authorities who do not have emergency budgets available to detect the VUI2020-12/01 strain reported to be currently fast-spreading in the UK.

Dec 21, 2020

Bionano Genomics Saphyr System Software Update

Bionano Genomics has released updated software for its Saphyr instrument that allows the system to image up to 96 human genomes per week to a depth of coverage of 100X, or nearly 5,000 samples per year. The update is preinstalled on new systems and will be made available free of charge to existing customers. It also includes Saphyr Assure, an automated system monitoring tool that continuously inspects data quality and instrument performance.

Dec 17, 2020

Autogen NeXTRACT 48

AutoGen has launched the NeXTRACT 48 platform for the rapid extraction of viral DNA and/or RNA from a variety of samples including viral transport media, universal viral transport, and sputum. NeXTRACT 48 is compatible with most COVID-19 real-time PCRs diagnostic kits, is compact and easily fits into a BSL2 environment, and can process 48 samples in 20 minutes or 800 samples or more per day, AutoGen said. The platform is ideal for labs looking to supplement COVID-19 viral RNA extractions or to add a back-up platform with a low capital investment and operating cost, with consumables costing less than $5 per sample, the Holliston, Massachusetts-based company said.

Dec 17, 2020

Personalis SHERPA, NEOPS

Personalis has launched its Systemic HLA Epitope Ranking Pan Algorithm (SHERPA) machine learning-based tool for identifying and characterizing cancer neoantigens, as well as its Neoantigen Presentation Score (NEOPS) for predicting  cancer immunotherapy response.

SHERPA assesses the potential MHC-binding affinity and stability of identified peptides, and incorporates features linked to antigen processing machinery and RNA abundance to produce a presentation rank for each detected peptide. The rank determines the relative likelihood of a given neoantigen being presented and undergoing immunosurveillance. Integrated into the firm's NeXT platform, the tool allows for the development of new neoantigen-based diagnostic biomarkers, such as its NEOPS biomarker, and neoantigen-targeting personalized cancer therapies.

Personalis' NEOPS combines the tumor genomic and immune-related analytics of the firm's NeXT platform to create a composite biomarker, that the firm believes can be more effective in predicting immunotherapy responses than other biomarkers.

NEOPS and SHERPA are the latest updates to the comprehensive suite of advanced analytical engines of the Personalis NeXT Platform for biopharmaceutical customers, the company said.

Dec 17, 2020

Invitae Exome Reanalysis

Invitae has begun offering customers of its exome sequencing service routine case-level reanalysis of their results every six months for a minimum of three years. This will ensure that patients' results are up to date based on the latest variant classification research. The reanalysis will be conducted by the company's team of genetics experts, who will utilize an artificial intelligence-powered diagnosis engine that Invitae garnered with the acqusition of Belgian firm Diploid, and a gene-phenotype database.

Dec 14, 2020

Celemics CRV Panel

Celemics has launched its CRV Panel, a multiplexed, target enrichment panel for next-generation sequencing-based identification of common human respiratory viruses, including SARS-CoV-2. The research-use-only assay detects a total of 39 strains of nine viruses including coronaviruses, rhinoviruses, influenzas, and respiratory syncytial viruses. The panel is bundled with non-cloud-based bioinformatics software that enables a complete workflow. The product is available in the US, Europe, Latin America, the Middle East, Singapore, Malaysia, and Thailand via Celemics' certified retailers.

Dec 11, 2020

ATCC SARS-CoV-2 External Control Kit

ATCC has introduced a SARS-CoV-2 External Control Kit for clinical laboratories and test manufacturers. The new kit enables clinical laboratories to meet federal regulations stipulating that they assess the performance of their testing applications. The kit comprises a universal, full-process positive control (a heat-inactivated virus) and negative control (human cell line) that allow clinocal labs to verify and assess the quality of their molecular diagnostic assays.

Dec 11, 2020

BioEcho EchoLution for Viral RNA and DNA Extraction

Köln, Germany-based BioEcho has launched the new EchoLution viral RNA and DNA extraction kit. The firm's reverse chromatography-based single-step extraction kits are available in 48- and 96-well formats and can extract nucleic acids in approximately two minutes.

The kit has been validated for SARS-CoV-2 RNA detection from nasopharyngeal samples.

Dec 10, 2020

Twist Bioscience Clonal-Ready Gene Fragments

Twist Bioscience has launched clonal-ready gene fragments. The synthetic DNA products are available with and without adapters and can be used to build constructs. Potential applications include cloning, gene and protein expression, pathway and enzyme engineering, and enzyme optimization.

Gene fragments begin as oligonucleotides, are annealed, and amplified to produce double-stranded DNA fragments. They are error-corrected in an enzymatic reaction. The error rate is 1 in 5,300 base pairs; for shorter oligonucleotides between 300 and 800 base pairs long, the error rate drops to 1 in 6,200.

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.

Jan
26
Sponsored by
LGC, Biosearch Technologies

Reduced representation next-generation sequencing (NGS) methods are driving understanding of both physical and structural variation in all species.

Jan
28
Sponsored by
Sophia Genetics

This webinar discusses how the University of Michigan has implemented a new next-generation sequencing (NGS) capture-based solution to assess myeloid malignancies while minimizing required laboratory resources. 

Feb
11
Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
17
Sponsored by
BioLegend

Host immune responses play a central role in controlling SARS-CoV-2 infection, but they remain incompletely characterized and understood.